Heeding the WHO, Kenya will suspend plans to treat Covid-19 patients with the controversial antimalarial drug hydroxychloroquine because early research shows it increases the risk of death. The country is now stuck with the 379,000 tablets imported from India late last month. Solidarity Trial is a WHO-led study to evaluate the safety and efficacy of four drugs and drug combinations against Covid-19 in 35 countries including Kenya. In Kenya, the trial is open to consenting adults above 18 years sick with Covid-19. The Pharmaceutical Society of Kenya backed the WHO but urged Kenyans to be more proactive in testing for Non-Communicable Diseases.

Source: The Star May 26, 2020 16:52 UTC